Fredrik Pehr Marmsater

This inventor holds 14 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Array Biopharma Inc., Eli Lilly and Company. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fredrik Pehr Marmsater. Retrieved from https://idiyas.com/inventor/fredrik-pehr-marmsater

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 35.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 27(Granted Patents)

Location History:

Longmont, CO (US) (2009 - 2010)
Boulder, CO (US) (2010 - 2020)

Company Filing History:

Eli Lilly and Company

patents

Years Active: 2009-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12171739 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2024-12-24),

2. 10780073 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2020-09-22),

3. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

4. 9693989 - N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases (2017-07-04),

5. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

6. 8987251 - Triazolopyridine compounds as PIM kinase inhibitors (2015-03-24),

7. 8895550 - Triazolopyridine compounds as PIM kinase inhibitors (2014-11-25),

8. 8841455 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors (2014-09-23),

9. 8575145 - Triazolopyridine compounds as PIM kinase inhibitors (2013-11-05),

10. 8557809 - Triazolopyridine compounds as PIM kinase inhibitors (2013-10-15),

11. 7816523 - Potentiators of glutamate receptors (2010-10-19),

12. 7803938 - Potentiators of glutamate receptors (2010-09-28),

13. 7678794 - Potentiators of glutamate receptors (2010-03-16),

14. 7598423 - Potentiators of glutamate receptors (2009-10-06),

Title: Fredrik Pehr Marmsater: Innovator in Pharmaceutical Chemistry

Introduction

Fredrik Pehr Marmsater is a notable inventor based in Boulder, Colorado, recognized for his contributions to pharmaceutical chemistry. With a total of 14 patents to his name, he has made significant strides in the development of compounds that target critical biological pathways.

Latest Patents

Among his latest innovations are the N4-phenyl-quinazoline-4-amine derivatives and related compounds, which serve as ErbB type I receptor tyrosine kinase inhibitors. These compounds are designed for the treatment of hyperproliferative diseases. The invention provides compounds of Formula I, wherein B, G, A, E, R, R, R, m, and n are defined, which are useful as type I receptor tyrosine kinase inhibitors. The methods of use of these compounds in treating hyperproliferative disorders in mammals are also outlined in his patents.

Career Highlights

Fredrik has worked with prominent companies in the pharmaceutical industry, including Array Biopharma Inc. and Eli Lilly and Company. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Fredrik has collaborated with talented individuals such as Qian Zhao and Joseph P. Lyssikatos. These partnerships have likely enhanced his research and development efforts in the field.

Conclusion

Fredrik Pehr Marmsater stands out as an influential inventor in the realm of pharmaceutical chemistry, with a focus on innovative treatments for serious health conditions. His work continues to impact the industry positively.

Profile summary based on public USPTO records.